{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-079165","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.987757+00:00","generated_at":"2026-05-31T04:22:13.339445+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity Therapeutics reports two ovarian cancer patients exceed one year on stenoparib therapy","bullets":["Two patients in Phase 2 trial for advanced recurrent ovarian cancer have exceeded one year on stenoparib.","Patients pre-screened using DRP companion diagnostic; show durable clinical benefit in heavily pre-treated population.","One confirmed complete response and long-term disease stability observed.","CEO notes extending life by 52 weeks is noteworthy for heavily pre-treated patients.","Company planning next phase of development, accelerating path toward regulatory approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-079165","json":"https://secwatch.observer/filing/0001213900-24-079165.json","markdown":"https://secwatch.observer/filing/0001213900-24-079165.md","text":"https://secwatch.observer/filing/0001213900-24-079165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024079165/0001213900-24-079165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024079165/ea021470501-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:22:13.339445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}